目的:基于乙二醛酶-1(GLO-1)/晚期糖基化终末产物(AGE)/晚期糖基化终末产物受体(RAGE)通路探讨糖痹康干膏防治2型糖尿病周围神经病变(DPN)的作用机制。方法:56只SD大鼠随机选取8只为正常组,其余48只大鼠予高脂饲料喂养联合腹腔注射链脲...目的:基于乙二醛酶-1(GLO-1)/晚期糖基化终末产物(AGE)/晚期糖基化终末产物受体(RAGE)通路探讨糖痹康干膏防治2型糖尿病周围神经病变(DPN)的作用机制。方法:56只SD大鼠随机选取8只为正常组,其余48只大鼠予高脂饲料喂养联合腹腔注射链脲佐菌素(STZ)诱导2型糖尿病(T2DM)模型,按血糖将大鼠随机分为模型组、唐林组(13.5 mg·kg^(-1))、二甲双胍组(135 mg·kg^(-1))和糖痹康干膏低、中、高剂量组(3、6、12 g·kg^(-1))。干预第4周模型组机械痛痛阈下降则DPN造模成功。每4周测定大鼠的空腹血糖、体质量、机械痛痛阈。干预16周,苏木素-伊红(HE)染色法观察坐骨神经病理形态,免疫组化法检测坐骨神经RAGE、AGE、蛋白激酶C(PKC)、胶原蛋白(COL)表达,实时荧光定量聚合酶链式反应(Real-time PCR)检测坐骨神经RAGE、PKC、Toll样受体(TLR)、COL、GLO-1 m RNA表达。酶联免疫吸附测定法(ELISA)检测大鼠血清天冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、肌酐(CREA)、尿素(UREA)、白细胞介素-6(IL-6)、肿瘤坏死因子(TNF)-α含量。结果:与正常组比较,模型组空腹血糖升高(P<0.01),体质量及机械痛痛阈降低(P<0.01),血清AST、ALT、CREA、UREA、IL-6、TNF-α升高(P<0.01),坐骨神经RAGE、AGE、PKC表达升高(P<0.01),COL表达降低(P<0.01),TLR、RAGE、PKC m RNA表达升高(P<0.01),COL、GLO-1 m RNA表达降低(P<0.01),坐骨神经形态不规则、轴索形态改变、髓鞘变性。与模型组比较,糖痹康干膏高剂量组各时间,中剂量组给药第4、16周空腹血糖降低(P<0.05,P<0.01);糖痹康干膏各剂量组体质量无明显变化;糖痹康干膏各剂量组在给药后不同时间出现痛阈升高(P<0.05,P<0.01);各剂量组血清IL-6、TNF-α含量下降(P<0.05,P<0.01);糖痹康干膏各剂量组坐骨神经中RAGE、AGE、PKC表达降低(P<0.01),COL表达升高(P<0.01),TLR、RAGE、PKC m RNA表达降低(P<0.01),GLO-1 m RNA表达升高(P<0.05,P<0.01),低、高剂量组COL m RNA表达升高(P<0.01),糖痹康干膏各剂量组病理表现均较模型组病变程度轻。结论:糖痹康干膏具有明显改善DPN作用,其机制可能与调控GLO-1/AGE/RAGE通路作用有关。展开更多
目的:探讨白花丹素作为一种新型的铁死亡诱导剂在膀胱癌抑制中的作用机制。方法:本研究中使用了膀胱癌细胞T24。采用细胞增殖与活性检测-8(CCK-8)法检测白花丹素(0.1、1、2、3、6、12、24、48μmol·L^(-1))对T24细胞活力的影响。...目的:探讨白花丹素作为一种新型的铁死亡诱导剂在膀胱癌抑制中的作用机制。方法:本研究中使用了膀胱癌细胞T24。采用细胞增殖与活性检测-8(CCK-8)法检测白花丹素(0.1、1、2、3、6、12、24、48μmol·L^(-1))对T24细胞活力的影响。采用膜联蛋白V-异硫氰酸荧光素/碘化丙啶(Annexin V FITC/PI)凋亡试剂盒检测白花丹素(1.5、3、6μmol·L^(-1))对T24细胞凋亡的影响。采用不同的抑制剂(铁死亡抑制剂Fer-1,凋亡抑制剂VAD,坏死性凋亡抑制剂Nec-1)与白花丹素(6μmol·L^(-1))联合使用。采用活性氧荧光探针(DCFH-DA),丙二醛(MDA)和谷胱甘肽(GSH)试剂盒分别检测不同浓度的白花丹素(1.5、3、6μmol·L^(-1))对T24细胞内活性氧水平,MDA和GSH的含量,脂质过氧化荧光探针(C11-BODIPY)荧光探针检测白花丹素(1.5、3、6μmol·L^(-1))对T24细胞中过氧化物水平的影响。蛋白免疫印迹法(Western blot)检测白花丹素(1.5、3、6μmol·L^(-1))细胞中溶质载体家族7成员11(SLC7A11)、谷胱甘肽过氧化酶(GPX4)、核因子E2相关因子-2(Nrf-2)和Kelch样ECH关联蛋白1(Keap1)的蛋白表达的影响。结果:与空白组比较,白花丹素组T24细胞的活性明显降低(P<0.05),IC50为3.52μmol·L^(-1)。与空白组比较,白花丹素组(1.5、3、6μmol·L^(-1))T24细胞凋亡率明显升高(P<0.05);与单独使用6μmol·L^(-1)的白花丹素组比较,铁死亡抑制剂和凋亡抑制剂组能够逆转6μmol·L^(-1)的白花丹素对T24细胞增殖抑制作用(P<0.05)。与空白组比较,白花丹素组(1.5、3、6μmol·L^(-1)),T24细胞ROS、MDA及脂质过氧化物的含量明显升高,GSH水平明显降低,铁死亡相关蛋白SLC7A11、GPX4以及Nrf-2/Keap1明显降低(P<0.05)。结论:白花丹素能诱导细胞铁死亡,其机制与Nrf-2/Keap1信号通路有关。展开更多
Objective With the increasing publication of clinical practice guidelines(CPG)for Traditional Chinese Medicine(TCM)and Integrated Traditional Chinese and Western Medicine(IM),the standardization and scientifiction of ...Objective With the increasing publication of clinical practice guidelines(CPG)for Traditional Chinese Medicine(TCM)and Integrated Traditional Chinese and Western Medicine(IM),the standardization and scientifiction of its formulation have gradually attracted many people’s attention.To offer an overview of TCM and IM CPGs published over the past decade and analyze their general characteristics and methodological quality.Methods The China National Knowledge Infrastructure(CNKI)and WANFANG databases were searched for clinical practice guidelines and expert consensus papers from January 2010 to June 2021.Two researchers independently completed the literature screening and cross-checking according to the inclusion and exclusion criteria of CPGs and extracted information on general characteristics and methodological quality of CPGs.Results According to the selection criteria,231 CPGs(EB-CPGs=119,CBCPGs=112)were selected and the number of CPGs published in the 11 years showed an overall upward trend.The vast majority of CPGs used the Western naming system for the diseases,and only 11 CPGs were named of TCM diseases or symptoms.TCM treatments were recommended in 223 CPGs.There were 156 ancient Chinese Medicine literature sources cited in 231 CPGs and opinions and experiences of 62 TCM experts cited in 37 CPGs.The methodological quality of EB-CPGs for TCM and IM were significantly better than CB-CPGs in 11 items.Only 60 EB-CPGs and 7 CB-CPGs designated clear criteria for grading quality of evidence and strength of the recommendations and 74 CPGs presented both the level of evidence and the strength of recommendations.We classified all CPGs according to whether or not they used GRADE,and the results showed that the CPGs using GRADE had higher methodological quality and more standardized reports.Conclusion This research has shown that the quantity and quality of CPGs in both TCM and IM have improved over the time span,but the methodological quality,especially evidence citation,and the use of criteria for grading quality of evidence and strength of the recommendations,still needs to further improvement in the future.展开更多
文摘目的:基于乙二醛酶-1(GLO-1)/晚期糖基化终末产物(AGE)/晚期糖基化终末产物受体(RAGE)通路探讨糖痹康干膏防治2型糖尿病周围神经病变(DPN)的作用机制。方法:56只SD大鼠随机选取8只为正常组,其余48只大鼠予高脂饲料喂养联合腹腔注射链脲佐菌素(STZ)诱导2型糖尿病(T2DM)模型,按血糖将大鼠随机分为模型组、唐林组(13.5 mg·kg^(-1))、二甲双胍组(135 mg·kg^(-1))和糖痹康干膏低、中、高剂量组(3、6、12 g·kg^(-1))。干预第4周模型组机械痛痛阈下降则DPN造模成功。每4周测定大鼠的空腹血糖、体质量、机械痛痛阈。干预16周,苏木素-伊红(HE)染色法观察坐骨神经病理形态,免疫组化法检测坐骨神经RAGE、AGE、蛋白激酶C(PKC)、胶原蛋白(COL)表达,实时荧光定量聚合酶链式反应(Real-time PCR)检测坐骨神经RAGE、PKC、Toll样受体(TLR)、COL、GLO-1 m RNA表达。酶联免疫吸附测定法(ELISA)检测大鼠血清天冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、肌酐(CREA)、尿素(UREA)、白细胞介素-6(IL-6)、肿瘤坏死因子(TNF)-α含量。结果:与正常组比较,模型组空腹血糖升高(P<0.01),体质量及机械痛痛阈降低(P<0.01),血清AST、ALT、CREA、UREA、IL-6、TNF-α升高(P<0.01),坐骨神经RAGE、AGE、PKC表达升高(P<0.01),COL表达降低(P<0.01),TLR、RAGE、PKC m RNA表达升高(P<0.01),COL、GLO-1 m RNA表达降低(P<0.01),坐骨神经形态不规则、轴索形态改变、髓鞘变性。与模型组比较,糖痹康干膏高剂量组各时间,中剂量组给药第4、16周空腹血糖降低(P<0.05,P<0.01);糖痹康干膏各剂量组体质量无明显变化;糖痹康干膏各剂量组在给药后不同时间出现痛阈升高(P<0.05,P<0.01);各剂量组血清IL-6、TNF-α含量下降(P<0.05,P<0.01);糖痹康干膏各剂量组坐骨神经中RAGE、AGE、PKC表达降低(P<0.01),COL表达升高(P<0.01),TLR、RAGE、PKC m RNA表达降低(P<0.01),GLO-1 m RNA表达升高(P<0.05,P<0.01),低、高剂量组COL m RNA表达升高(P<0.01),糖痹康干膏各剂量组病理表现均较模型组病变程度轻。结论:糖痹康干膏具有明显改善DPN作用,其机制可能与调控GLO-1/AGE/RAGE通路作用有关。
文摘目的:探讨白花丹素作为一种新型的铁死亡诱导剂在膀胱癌抑制中的作用机制。方法:本研究中使用了膀胱癌细胞T24。采用细胞增殖与活性检测-8(CCK-8)法检测白花丹素(0.1、1、2、3、6、12、24、48μmol·L^(-1))对T24细胞活力的影响。采用膜联蛋白V-异硫氰酸荧光素/碘化丙啶(Annexin V FITC/PI)凋亡试剂盒检测白花丹素(1.5、3、6μmol·L^(-1))对T24细胞凋亡的影响。采用不同的抑制剂(铁死亡抑制剂Fer-1,凋亡抑制剂VAD,坏死性凋亡抑制剂Nec-1)与白花丹素(6μmol·L^(-1))联合使用。采用活性氧荧光探针(DCFH-DA),丙二醛(MDA)和谷胱甘肽(GSH)试剂盒分别检测不同浓度的白花丹素(1.5、3、6μmol·L^(-1))对T24细胞内活性氧水平,MDA和GSH的含量,脂质过氧化荧光探针(C11-BODIPY)荧光探针检测白花丹素(1.5、3、6μmol·L^(-1))对T24细胞中过氧化物水平的影响。蛋白免疫印迹法(Western blot)检测白花丹素(1.5、3、6μmol·L^(-1))细胞中溶质载体家族7成员11(SLC7A11)、谷胱甘肽过氧化酶(GPX4)、核因子E2相关因子-2(Nrf-2)和Kelch样ECH关联蛋白1(Keap1)的蛋白表达的影响。结果:与空白组比较,白花丹素组T24细胞的活性明显降低(P<0.05),IC50为3.52μmol·L^(-1)。与空白组比较,白花丹素组(1.5、3、6μmol·L^(-1))T24细胞凋亡率明显升高(P<0.05);与单独使用6μmol·L^(-1)的白花丹素组比较,铁死亡抑制剂和凋亡抑制剂组能够逆转6μmol·L^(-1)的白花丹素对T24细胞增殖抑制作用(P<0.05)。与空白组比较,白花丹素组(1.5、3、6μmol·L^(-1)),T24细胞ROS、MDA及脂质过氧化物的含量明显升高,GSH水平明显降低,铁死亡相关蛋白SLC7A11、GPX4以及Nrf-2/Keap1明显降低(P<0.05)。结论:白花丹素能诱导细胞铁死亡,其机制与Nrf-2/Keap1信号通路有关。
基金This work was supported by the National Natural Science Foundation of China(No.82174230 and No.81904055).
文摘Objective With the increasing publication of clinical practice guidelines(CPG)for Traditional Chinese Medicine(TCM)and Integrated Traditional Chinese and Western Medicine(IM),the standardization and scientifiction of its formulation have gradually attracted many people’s attention.To offer an overview of TCM and IM CPGs published over the past decade and analyze their general characteristics and methodological quality.Methods The China National Knowledge Infrastructure(CNKI)and WANFANG databases were searched for clinical practice guidelines and expert consensus papers from January 2010 to June 2021.Two researchers independently completed the literature screening and cross-checking according to the inclusion and exclusion criteria of CPGs and extracted information on general characteristics and methodological quality of CPGs.Results According to the selection criteria,231 CPGs(EB-CPGs=119,CBCPGs=112)were selected and the number of CPGs published in the 11 years showed an overall upward trend.The vast majority of CPGs used the Western naming system for the diseases,and only 11 CPGs were named of TCM diseases or symptoms.TCM treatments were recommended in 223 CPGs.There were 156 ancient Chinese Medicine literature sources cited in 231 CPGs and opinions and experiences of 62 TCM experts cited in 37 CPGs.The methodological quality of EB-CPGs for TCM and IM were significantly better than CB-CPGs in 11 items.Only 60 EB-CPGs and 7 CB-CPGs designated clear criteria for grading quality of evidence and strength of the recommendations and 74 CPGs presented both the level of evidence and the strength of recommendations.We classified all CPGs according to whether or not they used GRADE,and the results showed that the CPGs using GRADE had higher methodological quality and more standardized reports.Conclusion This research has shown that the quantity and quality of CPGs in both TCM and IM have improved over the time span,but the methodological quality,especially evidence citation,and the use of criteria for grading quality of evidence and strength of the recommendations,still needs to further improvement in the future.
